<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.42" />
  <meta name="author" content="Ming Tommy Tang">

  
  
  
  
    
      
    
  
  <meta name="description" content="PURPOSE:Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described.EXPERIMENTAL DESIGN:Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients.RESULTS:In the 118 patients treated with osimertinib, 42 had molecular profiling at progression. T790M was preserved in 21 (50%) patients and lost in 21 (50%). EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases. MET amplification was the second most common alteration (14%). Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET. Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers. Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01). In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months. Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02). CONCLUSIONS:Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients">

  
  <link rel="alternate" hreflang="en-us" href="/publication/2018-09-18-egfr-nsclc/">

  


  

  
  
  <meta name="theme-color" content="#328cc1">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.6/css/academicons.min.css" integrity="sha256-uFVgMKfistnJAfoCUQigIl+JfUaP47GrRKjf6CTPVmw=" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  
  <link rel="stylesheet" href="/css/custom.css">
  

  
    <script>
      window.ga=window.ga||function(){(ga.q=ga.q||[]).push(arguments)};ga.l=+new Date;
      ga('create', 'UA-84019592-2', 'auto');
      
      ga('require', 'eventTracker');
      ga('require', 'outboundLinkTracker');
      ga('require', 'urlChangeTracker');
      ga('send', 'pageview');
    </script>
    <script async src="//www.google-analytics.com/analytics.js"></script>
    
    <script async src="https://cdnjs.cloudflare.com/ajax/libs/autotrack/2.4.1/autotrack.js" integrity="sha512-HUmooslVKj4m6OBu0OgzjXXr+QuFYy/k7eLI5jdeEy/F4RSgMn6XRWRGkFi5IFaFgy7uFTkegp3Z0XnJf3Jq+g==" crossorigin="anonymous"></script>
    
  

  
  <link rel="alternate" href="/index.xml" type="application/rss+xml" title="Chatomics">
  <link rel="feed" href="/index.xml" type="application/rss+xml" title="Chatomics">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/2018-09-18-egfr-nsclc/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@https://twitter.com/tangming2005">
  <meta property="twitter:creator" content="@https://twitter.com/tangming2005">
  
  <meta property="og:site_name" content="Chatomics">
  <meta property="og:url" content="/publication/2018-09-18-egfr-nsclc/">
  <meta property="og:title" content="Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC | Chatomics">
  <meta property="og:description" content="PURPOSE:Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described.EXPERIMENTAL DESIGN:Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients.RESULTS:In the 118 patients treated with osimertinib, 42 had molecular profiling at progression. T790M was preserved in 21 (50%) patients and lost in 21 (50%). EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases. MET amplification was the second most common alteration (14%). Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET. Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers. Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01). In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months. Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02). CONCLUSIONS:Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients"><meta property="og:image" content="/img/headers/EGFR_NSLC.png">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2018-09-18T00:00:00&#43;00:00">
  
  <meta property="article:modified_time" content="2018-09-18T00:00:00&#43;00:00">
  

  
  

  <title>Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC | Chatomics</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">Chatomics</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-right">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#about">
            
            <span>Home</span>
            
          </a>
        </li>

        
        

        
        
        
        
        

        <li class="nav-item">
          <a href="/#cv">
            
            <span>Newsletter</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#posts">
            
            <span>Posts</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#projects">
            
            <span>Projects</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#talks">
            
            <span>Talks &amp; Teachings</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#publications">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/#contact">
            
            <span>Contact</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  
<div class="article-header">
  
  
    <img src="/img/headers/EGFR_NSLC.png" class="article-banner" itemprop="image">
  

  <span class="article-header-caption">My caption 😄</span>
</div>



  <div class="article-container">
    <h1 itemprop="name">Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC</h1>
    <span class="pub-authors" itemprop="author">
      
      Xiuning Le, Sonam Puri, &hellip;, <strong>Ming Tang</strong> et.al
      
    </span>
    <span class="pull-right">
      
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Landscape%20of%20EGFR-Dependent%20and%20-Independent%20Resistance%20Mechanisms%20to%20Osimertinib%20and%20Continuation%20Therapy%20Beyond%20Progression%20in%20EGFR-Mutant%20NSCLC&amp;url=%2fpublication%2f2018-09-18-egfr-nsclc%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=%2fpublication%2f2018-09-18-egfr-nsclc%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=%2fpublication%2f2018-09-18-egfr-nsclc%2f&amp;title=Landscape%20of%20EGFR-Dependent%20and%20-Independent%20Resistance%20Mechanisms%20to%20Osimertinib%20and%20Continuation%20Therapy%20Beyond%20Progression%20in%20EGFR-Mutant%20NSCLC"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=%2fpublication%2f2018-09-18-egfr-nsclc%2f&amp;title=Landscape%20of%20EGFR-Dependent%20and%20-Independent%20Resistance%20Mechanisms%20to%20Osimertinib%20and%20Continuation%20Therapy%20Beyond%20Progression%20in%20EGFR-Mutant%20NSCLC"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Landscape%20of%20EGFR-Dependent%20and%20-Independent%20Resistance%20Mechanisms%20to%20Osimertinib%20and%20Continuation%20Therapy%20Beyond%20Progression%20in%20EGFR-Mutant%20NSCLC&amp;body=%2fpublication%2f2018-09-18-egfr-nsclc%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


    </span>

    

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">PURPOSE:Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC. However, resistance mechanisms to osimertinib have been incompletely described.EXPERIMENTAL DESIGN:Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib. Molecular profiling analysis was performed at the time of progression in a subset of the patients.RESULTS:In the 118 patients treated with osimertinib, 42 had molecular profiling at progression. T790M was preserved in 21 (50%) patients and lost in 21 (50%). EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases. MET amplification was the second most common alteration (14%). Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET. Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers. Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01). In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months. Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02). CONCLUSIONS:Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations. Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients</p>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Type</div>
          <div class="col-xs-12 col-sm-9">
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Publication</div>
          <div class="col-xs-12 col-sm-9">In <em>Clinical Cancer Research</em>, Clinical Cancer Research.</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            September, 2018
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row" style="padding-top: 10px">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading" style="line-height:34px;">Links</div>
          <div class="col-xs-12 col-sm-9">

            




<a class="btn btn-primary btn-outline" href="/files/papers/EGFR_NSLC.pdf" target="_blank" rel="noopener">
  PDF
</a>
















          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"><p>More detail can easily be written here using <em>Markdown</em> and $\rm \LaTeX$ math code.</p>
</div>

    


  </div>
</div>


<div class="article-container article-widget">
  <div class="post-nav">
  
  <div class="post-nav-item">
    <div class="meta-nav">Next</div>
    <a href="/publication/2018-10-05-hdac-inhibitor/" rel="next">Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia</a>
  </div>
  
  
  <div class="post-nav-item">
    <div class="meta-nav">Previous</div>
    <a href="/publication/2018-08-21-ptefb/" rel="prev">Positive Regulation of Transcription by Human ZMYND8 through Its Association with P-TEFb Complex</a>
  </div>
  
</div>

</div>


<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      &copy; 2018 Ming &lsquo;Tommy&rsquo; Tang &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    
    <script id="dsq-count-scr" src="//divingintogeneticsandgenomics.disqus.com/count.js" async></script>
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/go.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/bash.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/shell.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/python.min.js"></script>
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/languages/r.min.js"></script>
      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

